Somatic overgrowth associated with overexpression of insulin-like growth factor II.
about
Frequent loss of imprinting at the IGF2 and H19 genes in head and neck squamous carcinomaEpigenetic modification and uniparental inheritance of H19 in Beckwith-Wiedemann syndrome.Expression levels of insulin-like growth factors 1 and 2 in head and neck squamous cell carcinoma.Genetics of Beckwith-Wiedemann syndrome-associated tumors: common genetic pathways.Epigenotype-phenotype correlations in Beckwith-Wiedemann syndrome.Relaxation of insulin-like growth factor 2 imprinting and discordant methylation at KvDMR1 in two first cousins affected by Beckwith-Wiedemann and Klippel-Trenaunay-Weber syndromes.Chest wall hamartoma with Wiedemann-Beckwith syndrome: clinical report and brief review of chromosome 11p15.5-related tumors.Loss of imprinting and allelic switching at the DLK1-MEG3 locus in human hepatocellular carcinoma.Advances in geneticsDynamic expression patterns of imprinted genes in human embryonic stem cells following prolonged passaging and differentiation.Mouse mutant embryos overexpressing IGF-II exhibit phenotypic features of the Beckwith-Wiedemann and Simpson-Golabi-Behmel syndromesCoding mutations in p57KIP2 are present in some cases of Beckwith-Wiedemann syndrome but are rare or absent in Wilms tumorsDiagnosing Friedreich's ataxia.Identification of the Meg1/Grb10 imprinted gene on mouse proximal chromosome 11, a candidate for the Silver-Russell syndrome geneGenetic variations and normal fetal growth.Insulin-like growth factor-II is increased in systemic sclerosis-associated pulmonary fibrosis and contributes to the fibrotic process via Jun N-terminal kinase- and phosphatidylinositol-3 kinase-dependent pathwaysEvidence that Igf2 down-regulation in postnatal tissues and up-regulation in malignancies is driven by transcription factor E2f3Epigenetic changes at the insulin-like growth factor II/H19 locus in developing kidney is an early event in Wilms tumorigenesis.The human imprintome: regulatory mechanisms, methods of ascertainment, and roles in disease susceptibilityPlatelet-rich growth factor in oral and maxillofacial surgery.The prevalence of loss of imprinting of H19 and IGF2 at birth.Somatic deletion of the imprinted 11p15 region in sporadic persistent hyperinsulinemic hypoglycemia of infancy is specific of focal adenomatous hyperplasia and endorses partial pancreatectomy.IGF-II induced by hepatitis B virus X protein regulates EMT via SUMO mediated loss of E-cadherin in mice.Type I insulin-like growth factor receptor signaling in hematological malignancies.FISH mapping of the IGF2 gene in horse and donkey-detection of homoeology with HSA11.The INS 5' variable number of tandem repeats is associated with IGF2 expression in humans.Upregulation of IGF2 expression during vascular calcification.The evolution of genomic imprinting via variance minimization: an evolutionary genetic model.Is p57KIP2 mutation a common mechanism for Beckwith-Wiedemann syndrome or somatic overgrowth?Growing interest in overgrowth.Birth characteristics and Wilms tumors in children in the Nordic countries: a register-based case-control study.IGF2 DMR0 methylation, loss of imprinting, and patient prognosis in esophageal squamous cell carcinoma.Nephrogenic rests and the pathogenesis of Wilms tumor: developmental and clinical considerations.Association of the INS VNTR with size at birth. ALSPAC Study Team. Avon Longitudinal Study of Pregnancy and Childhood.Methylation sequencing analysis refines the region of H19 epimutation in Wilms tumor.Analysis of CDKN1C in Beckwith Wiedemann syndrome.Insulin-like growth factor II plays a central role in atherosclerosis in a mouse model.
P2860
Q28140252-A21EACAD-D957-428F-BB0B-0BC749812767Q33678779-313F19DF-51AE-4546-BD20-5511A9FE7949Q33850252-22761879-F7A1-44BA-B359-79151C9BFCFDQ33875930-4987E1F5-04AB-4D09-BF14-E4B1B70CCAECQ33927299-DF3A3CD4-8B67-4DC5-B6F2-0293883DC437Q34145399-19E9E338-0B1B-49CF-8AC7-0798A7623C9DQ34292385-38A671B8-4CD8-4699-A680-8488F22EA0E0Q34474525-420D7B39-C61C-4174-BF68-EE01E4E7873DQ34800017-87F7D4F5-E594-43BD-9807-50217D8E7AD8Q35045173-A6783DDA-EBE8-46F5-826F-19129DACC4B2Q35197831-F6D9D13F-F5A9-445F-8B3D-6A761E1D8DDCQ35249129-B8FC7C8B-64AC-4D0C-BC96-22C8C86CC3DDQ35258617-6FC69C8E-6F1C-4B02-A429-13C9DB4A8BF0Q35793734-EA82B77A-698C-4704-9A23-CA69AA95BD25Q36448002-2279BCE9-5B01-4C41-BDAC-C567B68151E1Q36691084-1B1C41D2-AF49-4046-BBE4-CAD13A99E855Q36762442-6A2B77BA-DE4D-4547-B3B0-95A9D245C26BQ36772949-54E06CC0-3FBE-4427-A3A3-6AC851A6FA35Q36931989-F4B6BECA-FC23-48D7-8450-5AE12A665210Q36978395-93B925A0-FF7F-46E6-99F3-E0ECF945DF87Q37022907-B35B6EF9-D97D-470D-B5FC-2D8E54E059BAQ37370991-EF50724E-9D1C-4753-9E90-BF8A826F9433Q37636729-AE00EF88-CB78-4041-89E7-9B4F17D4A5A1Q37702186-65F3A21F-79E8-4C52-8138-F23950759117Q38504209-5E388E4C-989F-4D2C-8A8E-18E39F9E5478Q41035608-00466F4B-8093-4B17-A34F-362E82ACD5EBQ41697749-CC25D53D-311D-49C9-AC0D-DA71AC476D1FQ41934365-04A8ADA0-A2C8-47D9-949E-35E0BD064B25Q41942603-840F54A8-1ED3-4CE0-A16F-B9082D5D3D07Q43102935-D67BDE69-1B66-4FFD-B189-783D920F1564Q44782576-28789581-556D-41DB-8387-6A0F432B23A9Q45895946-AB0AF9D9-5384-4565-830D-739A4EFE79EBQ46258683-569C0EC4-87ED-430A-99A6-5E23FB1A6755Q47289282-257C1ED3-2413-47DB-A868-22CC9EA91EB4Q47924478-08311F41-0F51-4F80-AF44-665E24221933Q52539681-7752604F-34A4-486B-BA30-7D464B0112E8Q52544667-CDE51144-B76B-4C3C-BB25-33AD49C97DCF
P2860
Somatic overgrowth associated with overexpression of insulin-like growth factor II.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
Somatic overgrowth associated with overexpression of insulin-like growth factor II.
@en
Somatic overgrowth associated with overexpression of insulin-like growth factor II.
@nl
type
label
Somatic overgrowth associated with overexpression of insulin-like growth factor II.
@en
Somatic overgrowth associated with overexpression of insulin-like growth factor II.
@nl
prefLabel
Somatic overgrowth associated with overexpression of insulin-like growth factor II.
@en
Somatic overgrowth associated with overexpression of insulin-like growth factor II.
@nl
P2093
P2860
P356
P1433
P1476
Somatic overgrowth associated with overexpression of insulin-like growth factor II.
@en
P2093
P2860
P2888
P304
P356
10.1038/NM0396-311
P407
P577
1996-03-01T00:00:00Z